The companies will use proprietary technology to enable the discovery of peptide-radioisotope conjugates
Ariceum Therapeutics and UCB have announced a research partnership agreement to establish and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumours and immune-related diseases.
An essential part of the collaboration will involve the companies utilising each other’s proprietary technology platforms to enable the discovery of peptide-radioisotope conjugates as treatments for a variety of cancers and immune-related diseases.
In addition, Ariceum will gain access to UCB’s experience in order to identify novel synthetic macrocyclic peptides by incorporating its mRNA-display technology platform, ExtremeDiversity.
Similarly, UCB will benefit from Ariceum’s expertise in the areas of radiochemistry and labelling technology, thereby enhancing its ability to study how this type of technology could lead to the discovery of differentiated products for immune-related diseases. Indeed, the agreement means that each company will have the opportunity to explore multiple targets.
Dhaval Patel, chief scientific officer at UCB, was encouraged the partnership: “The collaboration with Ariceum further enhances our strategic drug discovery capabilities and provides UCB with the opportunity to learn and explore the potential of this modality in our drive to continuously innovate. We look forward to working with Ariceum’s scientists and are eager to leverage the technology platforms and disease expertise at each company.”
Manfred Rüdiger, chief executive officer of Ariceum Therapeutics, reflected: “We are excited about this strategic collaboration between UCB and Ariceum which aims to broaden Ariceum’s pipeline with potentially several new programmes at discovery stage.”
He added: “Through this partnership, Ariceum will have access to a unique library that will be used to screen against targets of interest for oncology for which current targeted approaches have failed, while working with UCB on enabling targeted systemic radiotherapy approaches in other areas of severe diseases.”
by John Pinching
Source: pharmatimes.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
